-
1.发明授权INHIBITION OF NITRIC OXIDE-MEDIATED HYPOTENSION AND SEPTIC SHOCK WITH IRON-CONTAINING HEMOPROTEIN 失效抑制由一氧化氮介导性低血压与血红素蛋白感染性休克
公开(公告)号：EP0626859B1
公开(公告)日：1998-01-28
申请号：EP93905917.6
申请日：1993-02-16
IPC分类号： A61K38/16
CPC分类号： A61K38/42 , Y02A50/411
摘要： The invention is directed to a method for the prophylaxis or treatment of an animal for deleterious physiological effects such as systemic hypotension caused by nitric oxide production induced by a biological response modifier. Examples of such biological response modifiers include but are not limited to a cytokine and an endotoxin. The invention is also directed to a method for the treatment of septic shock.
-
2.发明公开INHIBITION OF NITRIC OXIDE-MEDIATED HYPOTENSION AND SEPTIC SHOCK WITH IRON-CONTAINING HEMOPROTEIN 失效抑制由一氧化氮介导性低血压与血红素蛋白感染性休克。
公开(公告)号：EP0626859A1
公开(公告)日：1994-12-07
申请号：EP93905917.0
申请日：1993-02-16
CPC分类号： A61K38/42 , Y02A50/411
摘要： The invention is directed to a method for the prophylaxis or treatment of an animal for deleterious physiological effects such as systemic hypotension caused by nitric oxide production induced by a biological response modifier. Examples of such biological response modifiers include but are not limited to a cytokine and an endotoxin. The invention is also directed to a method for the treatment of septic shock.
-
3.发明公开HUMAN SERUM ALBUMIN-PORPHYRIN COMPLEXES WITH THE ABILITY TO BIND OXYGEN AND THERAPEUTIC USES THEREOF 失效从复杂卟啉与HSA结合的能力氧气，以及它们的治疗用途
公开(公告)号：EP0775157A1
公开(公告)日：1997-05-28
申请号：EP95926627.0
申请日：1995-07-07
申请人： DUKE UNIVERSITY
发明人： BONAVENTURA, Joseph
CPC分类号： C07K14/795 , A61K38/00 , C07K14/765 , Y02A50/411 , Y10S530/83
摘要： The invention is directed to human serum albumin-porphyrin (HSA-P) complexes which are capable of reversible oxygen binding and their uses. These complexes may be used in applications requiring physiological oxygen carriers such as in blood substitute solutions, or in applications requiring plasma expanders. Methods for the production of these complexes are provided. In a specific example, HSA-P complexes are shown to exhibit reversible oxygen binding. In another example, the HSA-P complex does not exhibit appreciable vasoactivity.
-
公开(公告)号：EP0850053B1
公开(公告)日：2009-01-21
申请号：EP96931551.4
申请日：1996-09-13
申请人： Duke University
IPC分类号： A61K31/00 , A61K31/195 , A61K35/18
CPC分类号： A61K33/00 , A61K31/00 , A61K31/04 , A61K31/095 , A61K31/195 , A61K35/18 , A61K47/54 , A61K47/6445 , A61K47/6901 , C07K14/00 , G01N21/631 , G01N21/76 , G01N33/721 , Y02A50/411 , Y02A50/423
摘要： Red blood cells can be loaded with low molecular weight nitrosylating agents, such as S-nitrosothiols, to act as a delivery system for NO + groups to tissues. Loaded red blood cells can be used in methods of therapy for conditions which are characterized by abnormal O 2 metabolism of tissues, oxygen-related toxicity, abnormal vascular tone, abnormal red blood cell adhesion, or abnormal O 2 delivery by red blood cells. Such treatment of red blood cells can be extended to in vivo therapies, with the object to achieve an increase in the ratio of red blood cell S-nitrosothiol to hemoglobin.
-
公开(公告)号：EP0850053A1
公开(公告)日：1998-07-01
申请号：EP96931551.0
申请日：1996-09-13
IPC分类号： A61K31 , A61K35 , A61K38 , A61K47 , A61P5 , A61P7 , A61P11 , C07K14 , C12N5 , G01N21 , G01N33
CPC分类号： A61K33/00 , A61K31/00 , A61K31/04 , A61K31/095 , A61K31/195 , A61K35/18 , A61K47/54 , A61K47/6445 , A61K47/6901 , C07K14/00 , G01N21/631 , G01N21/76 , G01N33/721 , Y02A50/411 , Y02A50/423
摘要： Red blood cells can be loaded with low molecular weight nitrosylating agents, such as S-nitrosothiols, to act as a delivery system for NO + groups to tissues. Loaded red blood cells can be used in methods of therapy for conditions which are characterized by abnormal O 2 metabolism of tissues, oxygen-related toxicity, abnormal vascular tone, abnormal red blood cell adhesion, or abnormal O 2 delivery by red blood cells. Such treatment of red blood cells can be extended to in vivo therapies, with the object to achieve an increase in the ratio of red blood cell S-nitrosothiol to hemoglobin.
-
6.发明授权HUMAN SERUM ALBUMIN-PORPHYRIN COMPLEXES WITH THE ABILITY TO BIND OXYGEN AND THERAPEUTIC USES THEREOF 失效从复杂卟啉与HSA结合的能力氧气，以及它们的治疗用途
公开(公告)号：EP0775157B1
公开(公告)日：2001-10-31
申请号：EP95926627.1
申请日：1995-07-07
申请人： DUKE UNIVERSITY
发明人： BONAVENTURA, Joseph
IPC分类号： C07K1/32 , C07K14/765
CPC分类号： C07K14/795 , A61K38/00 , C07K14/765 , Y02A50/411 , Y10S530/83
摘要： The invention is directed to human serum albumin-porphyrin (HSA-P) complexes which are capable of reversible oxygen binding and their uses. These complexes may be used in applications requiring physiological oxygen carriers such as in blood substitute solutions, or in applications requiring plasma expanders. Methods for the production of these complexes are provided. In a specific example, HSA-P complexes are shown to exhibit reversible oxygen binding. In another example, the HSA-P complex does not exhibit appreciable vasoactivity.
-
7.发明公开METHODS FOR IMPROVING THERAPEUTIC EFFECTIVENESS OF AGENTS FOR THE TREATMENT OF SOLID TUMORS AND OTHER DISORDERS 失效方法BEBESSERUNG代理人的疗效实性肿瘤和其他疾病的治疗
公开(公告)号：EP0705098A1
公开(公告)日：1996-04-10
申请号：EP94917468.0
申请日：1994-05-23
CPC分类号： A61K41/0052 , A61K31/00 , A61K31/195 , A61K31/198 , A61K31/4045 , A61K38/42 , Y10S514/832 , Y10S514/833 , Y10S514/929 , Y10S514/93 , A61K2300/00
摘要： The present invention is directed to the use of an inhibitor of NO activity, such as a nitric oxide scavenger or an NO synthase inhibitor, as an antitumor therapy to reduce tumor blood flow and oxygenation. The invention is also directed to administration of a nitric oxide scavenger or a nitric oxide synthase inhibitor to enhance the effectiveness of tumor therapy with hypoxic or acidic chemotherapeutic agents or hyperthermia. The invention is also directed to the administration of a nitric oxide synthase substrate to a subject previously administered a nitric oxide synthase inhibitor, in order to selectively inhibit tumor perfusion. In a specific example, administration of cell free hemoglobin, a nitric oxide scavenger, in conjunction with mitomycin C, a hypoxic cytotoxin, results in a significant delay in tumor growth of a human tumor xenograft in a mouse compared to mitomycin C alone. In another example, the administration of an inhibitor of nitric oxide synthase followed by the administration of a substrate of the enzyme causes a specific irreversible reduction of tumor blood flow, while normal blood flow is restored.
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.012 秒)
